Cencora, Inc.
NYSE:CORMedical - Distribution
-$5.65 today
- Market cap
- $66.47B
- Beta
- 0.59
- P/E (TTM)
- 20.7
- EPS (TTM)
- $13.10
- Dividend yield
- 0.87%
Volume 1.20M
Average 1.78M
COR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cencora, Inc.NYSE: COR
Net Income · Q3 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $764.86M rose 10.9% year over year, behind the +32.7% change in trailing-twelve-month net income. Sequentially, it fell 53.4% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.
Context
- Net income amounted to 0.5% of revenue in FY2025, unchanged from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of $3.47B (+121.6%) for the fiscal year ending Sep 2026, a step up from the +3.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $764.86M-53.4% QoQ
- Last fiscal yearSep 2025
- $1.57B+3.2% YoY
- LTMJun 2026
- $2.63B+32.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.9% | +358.6% | +347.7 pp |
| 1 year | +3.2% | +121.6% | +118.4 pp |
| 3-year CAGR | -2.0% | +39.1% | +41.1 pp |
| 5-year CAGR | +27.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 1.57B USD
- Year-over-year change
- +3.2%
- 4-year CAGR
- +0.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 1.57B | +3.2% |
| FY2024 | 2024-09-30 | 1.52B | -13.0% |
| FY2023 | 2023-09-30 | 1.75B | +4.7% |
| FY2022 | 2022-09-30 | 1.67B | +7.9% |
| FY2021 | 2021-09-30 | 1.54B | — |
Net Income vs competitors
How COR compares with its peers on the latest reported figures
- COR's LTM Jun 2026 net income of $2.63B is the 2nd largest of the 5 companies compared; the peer median is $1.25B.
- Its year-over-year change of +32.7% is the 3rd highest of 5, against a peer median of +34.5%.
- Net income amounts to 0.8% of revenue for COR, versus a peer median of 2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.17B | +56.6% | +8.6% | 1.3% | |
| LTM Jun 2026 | $2.63B | +32.7% | -2.0% | 0.8% | |
| LTM Sep 2026 | $1.81B | +12.5% | +72.7% | 0.7% | |
| LTM Mar 2026 | $701.07M | +291.7% | — | 25.8% | |
| LTM Jun 2026 | $424M | +5.5% | -11.1% | 3.1% | |
| Peer median (excluding COR) | $1.25B | +34.5% | +8.6% | 2.2% | |
Competitors are the stored peer set for COR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | 1.54B | 1.67B | 1.75B | 1.52B | 1.57B |
| Depreciation & Amortization | 514.79M | 709.84M | 980.85M | 1.12B | 1.07B |
| Deferred Income Tax | 334.87M | 196.18M | (118.86M) | (102.32M) | 59.86M |
| Stock-Based Compensation | 99.59M | 93.4M | 124.62M | 148M | 147.96M |
| Change in Working Capital | 367.32M | (139.66M) | 874.54M | 298.69M | 35.42M |
| Accounts Receivables | (930.08M) | (1.66B) | (2.71B) | (2.78B) | (1.92B) |
| Inventory | (1.12B) | (665.37M) | (2.18B) | (1.48B) | (1.27B) |
| Accounts Payables | 2.05B | 3.32B | 6.1B | 4.97B | 3.69B |
| Other Working Capital | 364.58M | (1.14B) | (333.76M) | (405.47M) | (465.1M) |
| Other Non-Cash Items | (194.59M) | 176.79M | 304.89M | 502.21M | 995.64M |
| Operating Cash Flow | 2.67B | 2.7B | 3.91B | 3.48B | 3.88B |
| Capital Expenditures | (438.22M) | (496.32M) | (458.36M) | (487.17M) | (667.98M) |
| Acquisitions (Net) | (5.73B) | 120.28M | (2.15B) | (100.2M) | (4.29B) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 22.3M | 7.6M | 9M | (30.72M) | (17.44M) |
| Investing Cash Flow | (6.14B) | (368.44M) | (2.6B) | (618.1M) | (4.98B) |
| Debt Repayment | 2.22B | (923.1M) | (623.26M) | (385.45M) | 3.2B |
| Common Stock Issued | 198.75M | 93.91M | 61.15M | 37.84M | 29.13M |
| Common Stock Repurchased | (82.15M) | (483.7M) | (1.18B) | (1.49B) | (435.47M) |
| Dividends Paid | (366.65M) | (391.69M) | (398.75M) | (416.17M) | (437.08M) |
| Other Financing Activities | (13.66M) | (48.2M) | (80.69M) | (75.85M) | (103.14M) |
| Financing Cash Flow | 1.95B | (1.75B) | (2.22B) | (2.33B) | 2.25B |
| Effect of Forex Changes | (3.73M) | (57.85M) | 72.76M | 9.4M | (50.27M) |
| Net Change in Cash | (1.53B) | 523.41M | (840.65M) | 544.99M | 1.1B |
| Free Cash Flow | 2.23B | 2.21B | 3.45B | 3B | 3.21B |
Cencora, Inc.
NYSE:COR
Intrinsic Alpha fair value
Locked
Current Price
$348.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.